Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.33 USD | -1.52% | -2.58% | +11.78% |
05-30 | Caligan Partners Enters into a Cooperation Agreement with Anika Therapeutics | CI |
05-28 | Anika Therapeutics Approves $40 Million Share Repurchase Program | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 739.9 | 643.3 | 517.3 | 432.4 | 331.8 | 376.3 | - | - |
Enterprise Value (EV) 1 | 739.9 | 643.3 | 422.9 | 432.4 | 331.8 | 376.3 | 295.3 | 376.3 |
P/E ratio | 27.4 x | -26.8 x | 128 x | -29 x | -4.02 x | -237 x | 43.7 x | 40.5 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 6.46 x | 4.93 x | 3.5 x | 2.77 x | 1.99 x | 2.2 x | 2.07 x | 1.94 x |
EV / Revenue | 6.46 x | 4.93 x | 3.5 x | 2.77 x | 1.99 x | 2.2 x | 2.07 x | 1.94 x |
EV / EBITDA | 15 x | 26.9 x | 31.5 x | 34.3 x | 21.4 x | 14.3 x | 11.9 x | 10.3 x |
EV / FCF | 21.6 x | 56.3 x | 159 x | -141 x | - | 51.2 x | 23.1 x | 13.4 x |
FCF Yield | 4.62% | 1.78% | 0.63% | -0.71% | - | 1.95% | 4.33% | 7.44% |
Price to Book | - | - | 1.8 x | - | - | - | - | - |
Nbr of stocks (in thousands) | 14,269 | 14,215 | 14,437 | 14,610 | 14,641 | 14,857 | - | - |
Reference price 2 | 51.85 | 45.26 | 35.83 | 29.60 | 22.66 | 25.33 | 25.33 | 25.33 |
Announcement Date | 20/02/20 | 04/03/21 | 08/03/22 | 06/03/23 | 13/03/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 114.6 | 130.5 | 147.8 | 156.2 | 166.7 | 170.8 | 181.9 | 193.6 |
EBITDA 1 | 49.18 | 23.94 | 16.43 | 12.6 | 15.52 | 26.23 | 31.55 | 36.44 |
EBIT 1 | 37.11 | -28.32 | 2.615 | -19.4 | -87.64 | -5.378 | 10.4 | 6.873 |
Operating Margin | 32.38% | -21.71% | 1.77% | -12.42% | -52.58% | -3.15% | 5.72% | 3.55% |
Earnings before Tax (EBT) 1 | 36.12 | -28.62 | 2.427 | -18.75 | -85.33 | -3.548 | 10.69 | 10.46 |
Net income 1 | 27.19 | -23.98 | 4.134 | -14.86 | -82.67 | -3.684 | 8.513 | 9.348 |
Net margin | 23.73% | -18.38% | 2.8% | -9.51% | -49.6% | -2.16% | 4.68% | 4.83% |
EPS 2 | 1.890 | -1.690 | 0.2800 | -1.020 | -5.640 | -0.1067 | 0.5800 | 0.6250 |
Free Cash Flow 1 | 34.18 | 11.44 | 3.254 | -3.077 | - | 7.356 | 16.31 | 28 |
FCF margin | 29.82% | 8.77% | 2.2% | -1.97% | - | 4.31% | 8.97% | 14.46% |
FCF Conversion (EBITDA) | 69.49% | 47.78% | 19.8% | - | - | 28.05% | 51.71% | 76.84% |
FCF Conversion (Net income) | 125.69% | - | 78.71% | - | - | - | 191.62% | 299.48% |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 20/02/20 | 04/03/21 | 08/03/22 | 06/03/23 | 13/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 35.82 | 36.69 | 39.66 | 40.26 | 39.62 | 37.92 | 44.3 | 41.46 | 42.97 | 40.52 | 40.77 | 43.72 | 45.81 | 42.12 | 44.76 |
EBITDA 1 | -0.199 | 2.608 | 4.42 | 4.05 | 1.375 | -1.204 | 6.272 | 4.65 | 5.798 | 2.502 | 6.991 | 7.696 | 9.038 | 5.713 | 7.676 |
EBIT 1 | -9.123 | -3.554 | -3.381 | -5.798 | -6.667 | -12.55 | -3.631 | -7.674 | -63.78 | -5.063 | -2.359 | 0.3405 | 1.704 | -0.122 | 2.716 |
Operating Margin | -25.47% | -9.69% | -8.53% | -14.4% | -16.83% | -33.1% | -8.2% | -18.51% | -148.43% | -12.49% | -5.79% | 0.78% | 3.72% | -0.29% | 6.07% |
Earnings before Tax (EBT) 1 | -9.17 | -3.708 | -3.285 | -5.362 | -6.391 | -12.01 | -3.07 | -7.039 | -63.2 | -4.471 | -0.506 | 1.135 | 2.386 | 0.0687 | 3.036 |
Net income 1 | -5.793 | -2.933 | -2.843 | -4.175 | -4.908 | -10.35 | -2.741 | -6.576 | -63 | -4.514 | -0.1463 | 1.036 | 2.064 | -0.001 | 2.451 |
Net margin | -16.17% | -7.99% | -7.17% | -10.37% | -12.39% | -27.29% | -6.19% | -15.86% | -146.61% | -11.14% | -0.36% | 2.37% | 4.5% | -0% | 5.48% |
EPS 2 | -0.4000 | -0.2000 | -0.2000 | -0.2900 | -0.3400 | -0.7100 | -0.1900 | -0.4500 | -4.300 | -0.3100 | -0.0100 | 0.0700 | 0.1367 | - | 0.1633 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 08/03/22 | 05/05/22 | 03/08/22 | 08/11/22 | 06/03/23 | 09/05/23 | 08/08/23 | 02/11/23 | 13/03/24 | 08/05/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | 94.4 | - | - | - | 81 | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | 34.2 | 11.4 | 3.25 | -3.08 | - | 7.36 | 16.3 | 28 |
ROE (net income / shareholders' equity) | 10.7% | -8.55% | 1.48% | -5.19% | - | -3.1% | 5.6% | - |
ROA (Net income/ Total Assets) | 9.66% | -6.89% | 1.16% | -4.27% | - | -2.4% | 4.5% | - |
Assets 1 | 281.5 | 348.2 | 356.6 | 348.3 | - | 153.5 | 189.2 | - |
Book Value Per Share | - | - | 19.90 | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | 2.83 | 1.63 | 5.14 | 7.49 | - | 9.93 | 9.75 | 8 |
Capex / Sales | 2.47% | 1.25% | 3.48% | 4.79% | - | 5.81% | 5.36% | 4.13% |
Announcement Date | 20/02/20 | 04/03/21 | 08/03/22 | 06/03/23 | 13/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.78% | 376M | |
+2.99% | 95.18B | |
-4.34% | 37.55B | |
-10.41% | 33.75B | |
+75.79% | 28.2B | |
-14.61% | 15.63B | |
-3.46% | 13.63B | |
-12.31% | 11.5B | |
+184.77% | 10.81B | |
-54.13% | 9.23B |
- Stock Market
- Equities
- ANIK Stock
- Financials Anika Therapeutics, Inc.